M
Michael P. Fanucchi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 3
Citations - 681
Michael P. Fanucchi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Trabectedin & Soft tissue sarcoma. The author has an hindex of 3, co-authored 3 publications receiving 608 citations.
Papers
More filters
Journal ArticleDOI
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki,J. Kyle Wathen,Shreyaskumar Patel,Dennis A. Priebat,Scott H. Okuno,Brian L. Samuels,Michael P. Fanucchi,David C. Harmon,Scott M. Schuetze,Denise Reinke,Peter F. Thall,Robert S. Benjamin,Laurence H. Baker,Martee L. Hensley +13 more
TL;DR: Gem citabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma are found to have activity.
Journal ArticleDOI
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Jean-Yves Blay,Margaret von Mehren,Brian L. Samuels,Michael P. Fanucchi,Isabelle Ray-Coquard,Brigid Buckley,Leen Gilles,Claudia Lebedinsky,Yusri A. Elsayed,Axel Le Cesne +9 more
TL;DR: The maximum tolerated dose was the highest dose level with six or more patients in which less than one-third of the patients experienced severe neutropenia or DLT, and doxorubicin and trabectedin pharmacokinetics were not altered substantially with concomitant administration.
Journal ArticleDOI
Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): Safety and efficacy analysis
J.-Y. Blay,M. von Mehren,Brian L. Samuels,Michael P. Fanucchi,I.L. Ray-Coquard,B. Buckley,L. Gilles,Claudia Lebedinsky,Yusri A. Elsayed,A. Le Cesne +9 more
TL;DR: A dose escalation phase I study to determine the combination regimen that is tolerable and associated with manageable neutropenia with T in patients with metastatic or recurrent STS and preclinical synergy with D.